Profile 7: Multiple Sclerosis (MS)
In multiple sclerosis, FMT is investigational: it targets immune balance and gut symptoms but never replaces disease-modifying therapy and must be guided alongside your neurologist.
| Parameter | MS-specific detail |
|---|---|
| Evidence level | ★★☆☆☆ Early-stage. Observational data consistently show MS-associated gut dysbiosis; animal EAE models demonstrate microbiota-mediated immune modulation. Small case series and pilot trials in humans show tolerability and preliminary signals of benefit. No large RCTs completed. FMT for MS is investigational. |
| Mechanism of dysbiosis | Reduced regulatory T-cell-inducing commensals (Clostridia clusters IV and XIVa, Bacteroides fragilis polysaccharide A producers). Elevated Akkermansia in some MS subtypes (paradoxically associated with increased intestinal permeability in this context). Dysbiosis amplifies Th17/Treg imbalance, driving CNS autoimmunity. Intestinal permeability increases systemic microbial antigen exposure, potentially cross-reacting with myelin epitopes. |
| Primary microbiota targets | Restore Clostridia clusters IV and XIVa (Treg-inducing). Normalise intestinal permeability (tight junction support). Reduce pro-inflammatory Th17-inducing taxa. Support SCFA production for peripheral immune calibration. Modulate bile acid pool affecting nuclear receptor signaling relevant to myelination. |
| Protocol modification | Full 4-phase protocol. Immunomodulatory medications (interferons, natalizumab, ocrelizumab, etc.) — consult treating neurologist before FMT: some DMTs may impair engraftment by reducing immune integration of donor microbiota; others may be synergistic. Relapsing-remitting MS: avoid FMT initiation during active relapse. Progressive MS: longer maintenance protocols under evaluation. |
| Minimum transfer duration | 90 days minimum. Neuroimmunological outcomes require sustained microbiota-immune co-regulation. Preliminary protocols suggest 6–12-month maintenance phases for immune stabilisation. |
| Priority exposome focus | Vitamin D optimisation (critical in MS; VDR-microbiota interactions directly relevant). High-fiber, anti-inflammatory diet (Mediterranean or similar). Avoid smoking (independently worsens MS and dysbiosis). Stress management (psychological stress triggers both MS relapses and dysbiosis). Physical activity adapted to disability level — directly improves microbiota diversity. |
| Expected response timeline | Intestinal permeability markers: 6–12 weeks. Inflammatory biomarkers: 3–6 months. MS relapse frequency: not established as primary endpoint; requires long-term follow-up and neurological assessment. Fatigue (a key MS symptom): may improve within 8–12 weeks via gut-brain axis modulation. |
| Warning signs (MS-specific) | Any new neurological symptoms or worsening of existing deficits after FMT initiation — immediate neurological assessment required. Fever (potential pseudo-relapse trigger in MS — Uhthoff phenomenon). Urinary tract infections (common in MS, dysbiosis-mediated, may worsen after microbiota disruption before stabilisation). Severe fatigue worsening (distinguish from expected post-FMT adaptation vs. inflammatory relapse). |
Table 18 – Clinical profile: Multiple Sclerosis (MS) # Protocol parameters, evidence level, and clinical modifications specific to MS.
Note: FMT in MS is investigational. All treatment decisions must be made in conjunction with the patient's neurologist and MS care team. Disease-modifying therapies should not be interrupted without neurological guidance.
Engen et al. 2024 (Annals of Neurology) systematic review identifies three consistent MS-microbiota patterns: reduced Prevotella, reduced butyrate producers, reduced tryptophan-AhR[G] signaling activity [438]. Phase 2 FMT trials (small n) showed preliminary EDSS improvement. A phase 3 pivotal trial is awaited; clinical application remains experimental.
MS-FMT Clinical Considerations (2024)
- Indication window: relapsing-remitting MS (RRMS), on DMT, exacerbation-free for 6 months — preliminary evidence is most robust in this subgroup.
- Delivery route: capsule FMT with 8-week consolidation; intensive colonoscopic delivery is not recommended during active inflammation.
- Expected clinical signal: improvement in concomitant GI symptoms (constipation in ~40% of MS patients) is the primary short-term endpoint; EDSS stabilization is the long-term endpoint.
- Mechanistic framework: AhR-mediated immune modulation by indole derivatives[G] and the kynurenine pathway[G] reduces CNS inflammation.
Patients must be informed: MS-FMT is available exclusively under clinical trial protocols and does not replace DMT therapy (interferon, glatiramer, dimethyl fumarate, sphingosine-1-phosphate modulators).
References
[438] Engen PA, Zaferiou A, Rasmussen H et al. The Gut Microbiome in Multiple Sclerosis: 2024 Systematic Review and Therapeutic Targeting. Annals of Neurology. 2024. Link
This stroke-registry study evaluated whether post-stroke statin therapy reduces major vascular events in statin-naïve patients whose pre-stroke LDL-C was already below recommended targets (≤70 mg/dL for atherosclerotic stroke, ≤100 mg/dL for non-atherosclerotic stroke). 1,858 patients (mean age 67.9 ± 15.3; 61.4% men; 13.2% atherosclerotic stroke; baseline LDL-C 75.7 ± 17.0 mg/dL) were analyzed. 1,256 (67.7%) received post-stroke statins (23.5% low-to-moderate, 44.1% high intensity). Weighted Cox regression with stabilized inverse probability treatment weighting assessed the composite of recurrent stroke, myocardial infarction and death. Statin therapy was associated with significantly reduced risk of major vascular events, with high-intensity statins showing the greatest benefit. The findings support statin initiation after ischemic stroke even when baseline LDL-C is below target.